China’s 3SBio Shares Surge On Up To $6 Bln Cancer Drug Licensing Deal With Pfizer
(RTTNews) – Drug major Pfizer Inc. (PFE) announced late Monday that it has entered into an exclusive global, ex-China, licensing agreement with Chinese biopharmaceutical company 3SBio, Inc. (TRSBF) for cancer drug SSGJ-707 for up to $6 billion.